Profile data is unavailable for this security.
About the company
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
- Revenue in USD (TTM)0.00
- Net income in USD-10.32m
- Incorporated2019
- Employees2.00
- LocationTharimmune Inc1200 Route 22 EastBRIDGEWATER 08807United StatesUSA
- Phone+1 (302) 743-2995
- Fax+1 (302) 645-1280
- Websitehttps://tharimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics NV | 19.05m | -50.44m | 153.58m | 166.00 | -- | 2.32 | -- | 8.06 | -0.4851 | -0.4851 | 0.1834 | 0.6279 | 0.139 | -- | 9.70 | 114,745.40 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 160.06m | 31.00 | -- | 3.42 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 161.78m | 6.00 | -- | 3.86 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 164.56m | 14.00 | -- | 1.38 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| MDxHealth SA | 103.07m | -31.43m | 168.29m | 312.00 | -- | -- | -- | 1.63 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Tharimmune Inc | 0.00 | -10.32m | 169.03m | 2.00 | -- | 5.25 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 169.54m | 66.00 | -- | -- | -- | 87.98 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 171.81m | 246.00 | -- | 12.20 | -- | 3.70 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 172.68m | 166.00 | -- | 0.6828 | -- | 6.43 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 174.99m | 8.00 | -- | 17.95 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Galectin Therapeutics Inc | 0.00 | -37.44m | 177.94m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| C4 Therapeutics Inc | 30.11m | -119.08m | 183.17m | 110.00 | -- | 0.9079 | -- | 6.08 | -1.67 | -1.67 | 0.4225 | 2.08 | 0.0939 | -- | 3.57 | 273,709.10 | -37.12 | -26.50 | -42.35 | -29.90 | -- | -- | -395.51 | -310.19 | -- | -- | 0.00 | -- | 71.44 | 10.72 | 20.51 | -- | -33.16 | -- |
| SAB Biotherapeutics Inc | 114.70k | -21.37m | 183.29m | 63.00 | -- | 1.11 | 8.34 | 1,597.96 | -2.81 | -2.81 | 0.0043 | 3.48 | 0.001 | -- | 0.3492 | 1,820.64 | 15.80 | -- | 17.22 | -- | -- | -- | 16,338.04 | -- | -- | -- | 0.0197 | -- | -40.94 | -- | 19.17 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Tharimmune Inc's reporting currency: US Dollar USD
17.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Dec 2025 | 3.25m | 8.23% |
| Clear Street LLCas of 31 Dec 2025 | 1.67m | 4.23% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 765.83k | 1.94% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 390.95k | 0.99% |
| Marshall Wace LLPas of 31 Dec 2025 | 339.79k | 0.86% |
| Geode Capital Management LLCas of 31 Dec 2025 | 335.92k | 0.85% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 180.58k | 0.46% |
| Aristides Capital LLCas of 31 Dec 2025 | 83.50k | 0.21% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 36.62k | 0.09% |
| Drucker Wealth 3 0 LLCas of 31 Dec 2025 | 25.34k | 0.06% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
